Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

48.39 +1.31 (+2.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 384,510
Open 47.03
Bid (Size) 47.80 (1)
Ask (Size) 49.57 (1)
Prev. Close 47.08
Today's Range 46.90 - 48.64
52wk Range 32.51 - 52.96
Shares Outstanding 45,882,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
What 7 Analyst Ratings Have To Say About AtriCure
 
Via Benzinga

Performance

YTD
+7.92%
+7.92%
1 Month
+1.32%
+1.32%
3 Month
+25.30%
+25.30%
6 Month
+10.86%
+10.86%
1 Year
+15.88%
+15.88%

More News

Read More
AtriCure Reports First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
From AtriCure, Inc.
Via Business Wire
Analyst Ratings for AtriCure
Via Benzinga
Earnings Outlook For AtriCure
Via Benzinga
AtriCure to Announce First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
5 Analysts Have This to Say About AtriCure
Via Benzinga
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
From AtriCure, Inc.
Via Business Wire
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure: Q2 Earnings Insights
Via Benzinga
AtriCure Reports Second Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.